Social Media Ideas for Jnj

Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

Johnson & Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17 th, 2026. Management will participate in a Fireside Chat at 12:...

I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now

The company is firing on all cylinders.

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?

J&J has more than 28 sources of blockbuster revenue.

I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now

Looking for a dividend stock you can sleep well owning? Here's why Johnson & Johnson could be the long-term healthcare anchor your portfolio needs.

Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now

I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)

<![CDATA[M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquire...

Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?

Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff?

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?

These two high-quality dividend payers have had very different fortunes recently.

Johnson & Johnson to pay $5.5 bln to settle talc-related cancer lawsuits

Johnson & Johnson offers $5.5B talc lawsuit settlement

Johnson & Johnson proposes a $5.5B settlement to resolve 76,000 talc lawsuits alleging baby powder caused ovarian cancer. The post Johnson & Johnson offers $5.5B talc lawsu...

JnJ Executive Committee Changes

JnJ Executive Committee Changes Anonymous (not verified) Sat, 09/05/2026 - 12:48 field_thread_url https://cafepharma.com/boards/threads/jnj-executive-commi...

J&J axes eye disease gene therapy after key phase 2b readout

Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026.

JnJ Executive Committee Changes

JnJ Executive Committee Changes Anonymous (not verified) Wed, 08/12/2026 - 00:32 field_thread_url https://cafepharma.com/boards/threads/jnj-executive-commi...

J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s t...

Johnson & Johnson embarks on supply chain restructuring

The project, which is largely tied to the innovative medicine segment, will see the company exit certain facilities and incur costs of up to $750 million.

J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy

Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.58 billion. The deal puts J&J in the mix of pharmaceutical companies developing next-gen...

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Johnson & Johnson offers $5.5 billion to settle talc lawsuits

US pharmaceutical giant Johnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming that its talcum powder products caused ovarian cancer, the c...

J&J Says No To Reviving Stelara Case

Johnson & Johnson has asked the Fourth Circuit not to revive CareFirst's antitrust suit alleging the company tried to monopolize the market for the immunosuppressive drug Stela...